Amenorrhea and anovulation represent a spectrum of hypothalamic, pituitary, ovarian, and end-organ etiologies that must be differentiated through systematic hormonal and anatomical evaluation before treatment is initiated. NaProTECHNOLOGY integrates CrMS mucus charting with targeted biochemical testing to identify the level of dysfunction and guide ovulation induction or hormonal restoration appropriate to the specific cause.
can you get pregnant if you have no period, amenorrhea causes infertility, hypothalamic amenorrhea stress fertility treatment, high prolactin irregular periods pituitary microadenoma, premature menopause high FSH trying to conceive, Kallmann syndrome anosmia no period pregnancy, anovulation without period bone loss risk, Creighton charting no menstruation fertility workup
Cite this article
Hilgers, T. W. (2004). Chapter 45: Amenorrhea and Anovulation. The Medical and Surgical Practice of NaProTECHNOLOGY, 603-606.
Hilgers TW. Chapter 45: Amenorrhea and Anovulation. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:603-606.
Hilgers, T. W. "Chapter 45: Amenorrhea and Anovulation." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 603-606.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The CREIGHTON MODEL FertilityCare System (CrMS) rests on a decades-long body of research demonstrating that cervical mucus functions as a physiologically regulated biological valve, opening predictably at the periovulatory estrogen rise and closing in the post-Peak phase. Chapter 15 of Hilgers (2004) synthesizes hormonal, ultrasound, cytologic, and biophysical evidence to establish that a woman's external observation of her Peak Day reliably identifies the fertile window, and documents the system's effectiveness data for both achieving and avoiding pregnancy across a five-study meta-analysis of nearly 1,900 couples.
PCOSEpidemiology and PrevalenceMetabolic ReframeDefective Ovulatory Events
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
PCOS (polycystic ovary syndrome), increasingly designated PMOS (polycystic metabolic ovary syndrome) to reflect its metabolic complexity, is far more prevalent than its classic presentation suggests, affecting roughly six percent of reproductive-age women and carrying systemic consequences well beyond fertility disruption. This chapter from the foundational NaProTECHNOLOGY textbook maps the hormonal architecture of the condition, its ovulatory defect patterns, its frequent co-occurrence with endometriosis, and the restorative surgical and cycle-tracking approaches developed at the Pope Paul VI Institute.
Andrology/Male FactorCriteria and ClassificationMedical TreatmentSurgical Correction
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Male infertility plays a clinically significant role in a large share of couples who struggle to conceive, yet standard laboratory criteria for semen analysis were designed primarily to predict success with assisted reproduction, not natural fertility. NaProTECHNOLOGY approaches male factor as a diagnosable condition with identifiable root causes, applying medical and surgical options aimed at restoring sperm function and combining that work with fertility-awareness charting to maximize the couple's chances of natural conception.